Oral artemisinin monotherapy removal from the private sector in Eastern Myanmar between 2012 and 2014

Malaria Journal

Volumn 15, Issue 1, 2016, Pages

  Khin, Hnin Su Su ^a   Aung, Tin ^a   Thi, Aung ^b   White, Chris ^a,c  

^a POPULATION SERVICES INTERNATIONAL   (United States)

^b DEPARTMENT OF HEALTH   (Myanmar)

^c BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

Antimalarial drug resistance; Artemisinin combination therapy; Malaria elimination; Oral artemisinin monotherapy; Outlet survey; Subsidy

Indexed keywords

ANTIMALARIAL AGENT; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; CHLOROQUINE; PRIMAQUINE; ARTEMISININ DERIVATIVE;

ARTEMISININ COMBINATION THERAPY; ARTEMISININ MONOTHERAPY THERAPY REPLACEMENT; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; HEALTH AUXILIARY; HEALTH CARE FACILITY; HEALTH PROGRAM; HUMAN; INTERVIEW; MALARIA; MALARIA CONTROL; MYANMAR; PHARMACY; RESIDENTIAL CARE; SAMPLING; THERAPY; DRUG THERAPY; DRUG UTILIZATION; HEALTH SERVICES RESEARCH; ORAL DRUG ADMINISTRATION; PRIVATE SECTOR; PROCEDURES;

ADMINISTRATION, ORAL; ANTIMALARIALS; ARTEMISININS; CROSS-SECTIONAL STUDIES; DRUG THERAPY; DRUG UTILIZATION; HEALTH SERVICES RESEARCH; HUMANS; MALARIA; MYANMAR; PRIVATE SECTOR;

EID: 84969847984     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/s12936-016-1292-8     Document Type: Article

References (31)

1. WHO. World Malaria Report. Geneva: World Health Organization; 2015.
2. WHO, Global Malaria Programme. Stop the marketing of oral artemisinin-based monotherapies: The World Health Organization (WHO) urges regulatory measures to stop marketing of oral artemisinin-based monotherapies and to promote access to artemisinin-based combination therapies (ACTs). Geneva: World Health Organization; 2010.
3. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455-67.
4. Amaratunga C, Sreng S, Suon S, Phelps ES, Stepniewska K, Lim P, et al. Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect Dis. 2012;12:851-8. doi: 10.1016/S1473-3099(12)70181-0.
5. Phyo AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, et al. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet. 2012;379:1960-6. doi: 10.1016/S0140-6736(12)60484-X.
6. Takala-Harrison S, Jacob CG, Arze C, Cummings MP, Silva JC, Dondorp AM, et al. Independent emergence of artemisinin resistance mutations among Plasmodium falciparum in Southeast Asia. J Infect Dis. 2015;211:670-9. doi: 10.1093/infdis/jiu491.
7. Kyaw MP, Nyunt MH, Chit K, Aye MM, Aye KH, Aye MM, et al. Reduced susceptibility of Plasmodium falciparum to artesunate in southern Myanmar. PLoS One. 2013;8:e57689. doi: 10.1371/journal.pone.0057689.
8. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371:411-23. doi: 10.1056/NEJMoa1314981.
9. Tun KM, Imwong M, Lwin KM, Win AA, Hlaing TM, Hlaing T, et al. Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. Lancet Infect Dis. 2015;15:415-21. doi: 10.1016/s1473-3099(15)70032-0.
10. World Health Organization and the National Malaria Control Programme Myanmar. Strategic Framework for Artemisinin Resistance Containment in Myanmar (MARC) 2011-2015. 2011.
11. World Health Organization. External evaluation of the National Malaria Control Programme. Geneva: World Health Organization; 2012.
12. Hlaing T, Wai KT, Oo T, Sint N, Min T, Myar S, et al. Mobility dynamics of migrant workers and their socio-behavioral parameters related to malaria in Tier II, artemisinin resistance containment zone, Myanmar. BMC Public Health. 2015;15:886. doi: 10.1186/s12889-015-2241-0.
13. Tatem AJ, Smith DL, Gething PW, Kabaria CW, Snow RW, Hay SI. Ranking of elimination feasibility between malaria-endemic countries. Lancet. 2010;376:1579-91. doi: 10.1016/s0140-6736(10)61301-3.
14. Population services International/Myanmar. A rapid supply chain in eastern Myanmar. 2012.
15. Population services International/Myanmar. Artemisinin monotherapy replacement project. 2015.
16. Xu JW, Xu QZ, Liu H, Zeng YR. Malaria treatment-seeking behaviour and related factors of Wa ethnic minority in Myanmar: a cross-sectional study. Malar J. 2012;11:417. doi: 10.1186/1475-2875-11-417.
17. WHO. Draft strategy for malaria elimination in the Greater Mekong subregion (2015-2030). Geneva: World Health Organization; 2015.
18. Shewchuk T, O'Connell KA, Goodman C, Hanson K, Chapman S, Chavasse D. The ACTwatch project: methods to describe anti-malarial markets in seven countries. Malar J. 2011;10:325. doi: 10.1186/1475-2875-10-325.
19. Littrell M, Gatakaa H, Phok S, Allen H, Yeung S, Chuor CM, et al. Case management of malaria fever in Cambodia: results from national anti-malarial outlet and household surveys. Malar J. 2011;10:328. doi: 10.1186/1475-2875-10-328.
20. O'Connell KA, Gatakaa H, Poyer S, Njogu J, Evance I, Munroe E, et al. Got ACTs? Availability, price, market share and provider knowledge of anti-malarial medicines in public and private sector outlets in six malaria-endemic countries. Malar J. 2011;10:326. doi: 10.1186/1475-2875-10-326.
21. O'Connell KA, Poyer S, Solomon T, Munroe E, Patouillard E, Njogu J, et al. Methods for implementing a medicine outlet survey: lessons from the anti-malarial market. Malar J. 2013;12:52. doi: 10.1186/1475-2875-12-52.
22. Palafox B, Patouillard E, Tougher S, Goodman C, Hanson K, Kleinschmidt I, et al. Understanding private sector antimalarial distribution chains: a cross-sectional mixed methods study in six malaria-endemic countries. PLoS One. 2014;9:e93763. doi: 10.1371/journal.pone.0093763.
23. Population services International/Myanmar and ACTwatch. Study reference document: Myanmar outlet survey 2014. 2015.
24. Population services International/Myanmar. Artemisinin Monotherapy Replacement Project: program brief. 2014.
25. Tougher S, Ye Y, Amuasi JH, Kourgueni IA, Thomson R, Goodman C, et al. Effect of the Affordable Medicines Facility-malaria (AMFm) on the availability, price, and market share of quality-assured artemisinin-based combination therapies in seven countries: a before-and-after analysis of outlet survey data. Lancet. 2012;380:1916-26. doi: 10.1016/s0140-6736(12)61732-2.
26. Cleary JD. Impact of pharmaceutical sales representatives on physician antibiotic prescribing. J Pharm Technol. 1992;8:27-9.
27. Population Services International/Myanmar. Malaria Household Survey Report 2014. 2015.
28. Willey BA, Tougher S, Ye Y, Mann AG, Thomson R, Kourgueni IA, et al. Communicating the AMFm message: exploring the effect of communication and training interventions on private for-profit provider awareness and knowledge related to a multi-country anti-malarial subsidy intervention. Malar J. 2014;13:46. doi: 10.1186/1475-2875-13-46.
29. Norris PH, Herxheimer A, Lexchin J, Mansfield P. Drug promotion: what we know, what we have yet to learn. Reviews of materials in the WHO/HAI database on drug promotion. Geneva: World Health Organization; 2004.
30. Datti B, Carter MW. The effect of direct-to-consumer advertising on prescription drug use by older adults. Drugs Aging. 2006;23:71-81.
31. ACTwatch Group, Novotny J, Singh A, Dysoley L, Sovannaroth S, Rekol H. Evidence of successful malaria case management policy implementation in Cambodia: results from national ACTwatch outlet surveys. Malar J. 2016;15(1):194. doi: 10.1186/s12936-016-1200-2.